MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock under...
$46,392K
Proceeds from exercises
of stock options
$5,612K
(1331.63%↑ Y/Y)
Proceeds from exercises
of warrants, net of...
$39K
(-99.72%↓ Y/Y)
Net cash provided by
financing activities
$52,100K
(251.86%↑ Y/Y)
Net increase
(decrease) in cash and cash...
$33,301K
(384.89%↑ Y/Y)
Canceled cashflow
$18,799K
Stock-based compensation
$4,973K
(-54.25%↓ Y/Y)
Accrued liabilities
$1,052K
Non-cash lease expense
$317K
Amortization of intangible
assets
$166K
(-50.15%↓ Y/Y)
Accounts payable
$139K
Depreciation
$88K
(-60.54%↓ Y/Y)
Accounts receivable
-$43K
Other
-$12K
Other non-current
assets
-$4K
Net cash used in
operating activities
-$18,709K
(28.94%↑ Y/Y)
Net cash used in
investing activities
-$90K
(46.43%↑ Y/Y)
Canceled cashflow
$6,794K
Net loss
-$24,657K
Purchases of property and
equipment
$90K
(-39.19%↓ Y/Y)
Prepaid expenses and
other current assets
$433K
Lease liabilities,
net
-$383K
Inventory
$30K
Back
Back
Cash Flow
PULSE BIOSCIENCES, INC. (PLSE)
PULSE BIOSCIENCES, INC. (PLSE)
source: myfinsight.com